| J9271 | Injection, pembrolizumab, 1 mg | 16,400 | $40 | $705.2K |
| J0897 | Injection, denosumab, 1 mg | 8,940 | $20 | $169.9K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 5,900 | $20 | $94.4K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 620 | $90 | $55.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 470 | $110 | $52.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 510 | $100 | $51.1K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 420 | $70 | $29.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13,970 | $1 | $27.9K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 170 | $100 | $15.9K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 90 | $140 | $12.7K |